Chimeric antigen receptor comprising an antigen binding domain specific for msln having a specificity for tumor cells

Patent metadata

Field	Value
Publication number	US-2023390393-A1
Application number	US-202118033335-A
Country	US
Kind code	A1
Filing date	Nov 2, 2021
Priority date	Nov 4, 2020
Publication date	Dec 7, 2023
Grant date	—

Abstract

The present invention is directed to a chimeric antigen receptor (CAR), comprising an antigen binding domain specific for MSLN in combination with one or more antigen binding domains specific for an antigen selected from the group consisting of CLA, CD66c, TSPAN8 and CD318; cell populations expressing such CARs and the use of the cell populations for cancer therapy.

First claim

1 . A chimeric antigen receptor (CAR), comprising an antigen binding domain specific for MSLN in combination with one or more antigen binding domains specific for an antigen selected from the group consisting of CLA, CD66c, TSPAN8 and CD318.

2 . A chimeric antigen receptor (CAR) according to claim 1 , characterized in that the CAR comprises an antigen binding domain specific for MSLN in combination with at least two antigen binding domains specific for at least two different antigens selected from the group consisting of CLA, CD66c, TSPAN8 and CD318.

3 . A chimeric antigen receptor (CAR) according to claim 1 or 2 , characterized in that the CAR comprises an antigen binding domain, a transmembrane domain and an intracellular signaling domain and wherein the intracellular signaling domain is triggered by binding of the antigen binding domain specific for MSLN or one antigen binding domain specific for an antigen selected from the group consisting of CLA, CD66c, TSPAN8 and CD318 to the appropriate antigens.

4 . A chimeric antigen receptor (CAR) according to at least one of the claims 1 to 3 , characterized in that the CAR comprises an antigen binding domain, an transmembrane domain and an intracellular signaling domain and comprising an antigen binding domain specific for MSLN in combination with one or more antigen binding domains specific for an antigen selected from the group consisting of CLA, CD66c, TSPAN8 and CD318 which are conjugated to the same or a different transmembrane domain and/or intracellular signaling domain.

5 . A chimeric antigen receptor (CAR) according to at least one of the claims 1 to 4 , characterized in that the transmembrane domain comprises a sequence of the transmembrane domains of 4-1BB, CD8 and/or CD28; and the intracellular signaling domain comprises a sequence of the intracellular signaling domains of one or more of CD28, CD137 and CD3zeta.

6 . A chimeric antigen receptor (CAR) according to at least one of the claims 1 to 5 , characterized in that in that the CAR comprises an anti-tag binding region which can bind to a tag which is coupled to an antigen binding domain specific for one or more antigens selected from the group consisting of MSLN, CLA, CD66c, TSPAN8 and CD318.

7 . A chimeric antigen receptor (CAR) according to at least one of the claims 1 to 5 , characterized in that in that the CAR comprises an anti-tag binding region which can bind to a tag which is coupled to an antigen binding domain specific for MSLN in combination with at least two antigen binding domains specific for at least two different antigens selected from the group consisting of CLA, CD66c, TSPAN8 and CD318.

8 . Method of binding a cancer cell with a CAR according to at least one of the claims 1 to 7 .

9 . A population of engineered cells expressing at least one CAR according to at least one of the claims 1 to 7 .

10 . Use of the population of engineered cells according to claim 9 for treatment of human cancer.

11 . A pharmaceutical composition comprising a population of engineered cells expressing a CAR according to at least one of the claims 1 to 7 .

12 . Use of the pharmaceutical composition according to claim 11 for treatment of human cancer.

13 . Use of the pharmaceutical composition according to claim 11 in combination with a chemotherapeutic, radiation, or immunomodulatory agent for treatment of cancer.

Assignees

• Miltenyi Biotec Bv & Co Kg

Inventors

• Hardt Olaf
• Bosio Andreas

Classifications

• A61K40/4255

  Mesothelin [MSLN] · CPC title

• A61K40/4224

  Molecules with a "CD" designation not provided for elsewhere · CPC title

• A61K40/4202

  Receptors, cell surface antigens or cell surface determinants · CPC title

• A61K40/31

  Chimeric antigen receptors [CAR] · CPC title

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title